NCCN Guidelines (R) Insights Thyroid Carcinoma, Version 2.2018 Featured Updates to the NCCN Guidelines

Haddad, RI; Nasr, C; Bischoff, L; Busaidy, NL; Byrd, D; Callender, G; Dickson, P; Duh, QY; Ehya, H; Goldner, W; Haymart, M; Hoh, C; Hunt, JP; Iagaru, A; Kandeel, F; Kopp, P; Lamonica, DM; McIver, B; Raeburn, CD; Ridge, JA; Ringel, MD; Scheri, RP; Sha

Haddad, RI (reprint author), Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018; 16 (12): 1429

Abstract

The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hurthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E-mutated anaplastic thyroid carcinoma.

Download PDF


Full Text Link